相关实验视频
Updated: Jan 10, 2026

10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
12.0K
阳性EBV扩散型大B细胞淋巴瘤 (DLBCL):评估和路线图
Pierluigi Porcu1, Rebecca Masel2, Nicholas Kendsersky3
1Division of Hematology and BMT, Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, Kentucky, USA.
Journal of medical virology
|November 27, 2025
概括
爱斯坦-巴尔病毒 (EBV) 在5-15%的扩散性大B细胞淋巴瘤 (DLBCL) 病例中被发现. 阳性EBVDLBCL具有独特的特征,EBV是一种预后生物标志物,正在进行针对性治疗的研究.
科学领域:
- 在瘤学瘤学.
- 病毒学 病毒学
- 免疫学 免疫学 免疫学
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是全球最常见的淋巴瘤.
- 爱斯坦-巴尔病毒 (EBV) 与各种人类癌症有关.
- 在免疫能力强的个体中,EBV DNA存在于DLBCL瘤的5-15%.
研究的目的:
- 审查EBV阳性DLBCL的当前临床和分子数据.
- 讨论针对DLBCL中的EBV的新型治疗策略.
- 确定EBV阳性DLBCL研究中的关键未解答问题.
主要方法:
- 对EBV阳性DLBCL最近的临床和分子研究的文献综述.
- 对现代化疗免疫治疗对EBV阳性DLBCL的影响分析.
- 探索独特的突变景观和免疫微环境.
主要成果:
- 具有EBV阳性的DLBCL表现出明显的临床特征,瘤微环境 (TME) 和历史上较差的生存率.
- 现代治疗已经完善了对EBV阳性DLBCL的理解和结果.
- 在DLBCL中,EBV被证实是独立的预后生物标志物.
结论:
- 阳性DLBCL是一种独特的临床病理学实体.
- 进一步的研究对于开发有针对性的EBV疗法至关重要.
- 了解EBV的作用是改善DLBCL患者治疗结果的关键.
关键词:
DLBCL DLBCL 是一个字母.这是EBV的EBV.全球性的全球性的全球性的全球性的全球性具有免疫能力的免疫能力.免疫性受损的人.免疫疗法 免疫疗法延迟时间 延迟时间这是一部诗歌,Lytic lytic.微观环境是一个微观环境.更多相关视频
相关概念视频
Primary Lymphoid Organs
14.5K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
14.5K
B Cell Activation and Differentiation
15.8K
The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
15.8K

